NUVB Stock Risk & Deep Value Analysis
Nuvation Bio Inc
Healthcare • Biotechnology
DVR Score
out of 10
What You Need to Know About NUVB Stock
We analyzed Nuvation Bio Inc using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran NUVB through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Aggressive. Here's what we found.
NUVB Risk Analysis & Red Flags
What Could Go Wrong
The company is operating with significant negative free cash flow (-$182M TTM) and net losses (-$204.63M FY25). If the commercial ramp-up of IBTROZI® fails to accelerate rapidly enough to offset the high operating expenses, or if pipeline assets face setbacks, Nuvation Bio will need to raise substantial additional capital, potentially leading to significant shareholder dilution that could depress the stock price.
Risk Matrix
Overall
Aggressive
Financial
High
Market
Medium
Competitive
Medium
Execution
Medium
Regulatory
Medium
Red Flags
- ⚠
Sustained negative Free Cash Flow (FCF) and Operating Cash Flow (OCF) without a clear, near-term path to profitability.
- ⚠
Director Kerry Wentworth's significant sale of 200,000 shares (79.05% of direct stake) on April 6, 2026, via Rule 10b5-1 plan, while pre-planned, still represents a reduction in insider conviction.
- ⚠
High P/S ratio (~25.1x TTM) for a company that is deeply unprofitable and in early commercialization, indicating high future growth expectations are already priced in.
Upcoming Risk Events
- 📅
Slower-than-expected IBTROZI® commercial ramp-up or sales deceleration
- 📅
Negative or inconclusive results from ongoing clinical trials (NUV-868, NUV-520)
- 📅
Competitive pressure from new or existing ROS1+ NSCLC treatments
When to Reconsider
- 🚪
Exit if IBTROZI® net product revenue fails to show strong sequential growth (e.g., less than 20% QoQ) in Q1/Q2 2026 earnings reports.
- 🚪
Sell if the company announces a capital raise that results in greater than 20% share dilution without a corresponding increase in market cap.
- 🚪
Exit if there are significant clinical setbacks for NUV-868 or NUV-520, which are key to the long-term pipeline.
Unlock NUVB Risk Analysis & Red Flags
Create a free account to see the full analysis
What Does Nuvation Bio Inc (NUVB) Do?
Market Cap
$1.58B
Sector
Healthcare
Industry
Biotechnology
Employees
291
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutic candidates for oncology. Its lead product candidate is taletrectinib, an ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer. The company is also developing Safusidenib, an inhibitor of mutant isocitrate dehydrogenase 1 in phase 2 clinical trials; NUV-1511, a drug-drug conjugate for use in chemotherapy agent that suppresses the growth of various advanced solid tumors; and NUV-868, a binding domain 2 bromodomain and extra-terminal inhibitor that inhibits bromodomain-containing protein 4. The company was founded in 2018 and is headquartered in New York, New York.
Visit Nuvation Bio Inc WebsiteInvestment Thesis
Nuvation Bio is transitioning into a commercial-stage oncology leader, driven by the successful launch and global expansion of IBTROZI® (taletrectinib) and a promising precision oncology pipeline including NUV-868 and NUV-520. The recent Q4 revenue beat, EMA validation, and upcoming AACR data presentation provide strong catalysts for significant revenue growth and a re-rating towards its potential as a specialized oncology powerhouse, despite near-term cash burn.
Is NUVB Stock Undervalued?
Unlock the full AI analysis for NUVB
Get the complete DVR score, risk analysis, and more
Unlock the full report
Create a free account to see the DVR score, risk flags, and AI analysis.
NUVB Price Targets & Strategy
12-Month Target
$8.50
Bull Case
$12.00
Bear Case
$3.00
Valuation Basis
Based on 30x forward P/S applied to estimated FY2026 revenue of $100M ($3.0B market cap / 348M shares outstanding).
Entry Strategy
Consider dollar-cost averaging in the $4.00-$4.50 range, seeking support near the current price level, which has shown volatility but held above key lows after initial Q4 earnings reaction.
Exit Strategy
Take initial profits at $8.00-$9.00; reassess at $12.00. Implement a stop-loss order if the stock drops below $3.50, indicating significant breakdown in investor confidence or fundamental deterioration.
Portfolio Allocation
7-10% for aggressive risk tolerance, 3-5% for moderate risk tolerance.
Price Targets & Strategy
Upgrade to Premium for price targets and entry/exit strategies
Is NUVB Financially Healthy?
Valuation
P/E Ratio
-7.70
Forward P/E
-33.92
Price/Sales
25.10
Profitability
Gross Margin
85.22%
Net Margin
-325.31%
EPS
$-0.60
Balance Sheet
Debt/Equity
0.20
Other
Beta (Volatility)
1.64
Does NUVB Have a Competitive Moat?
Sign in to unlockMoat Rating
🛡️ Narrow
Moat Trend
Expanding
Moat Sources
1 Identified
The moat is primarily derived from patent protection on IBTROZI® and other pipeline candidates, providing exclusivity for a period. Its durability depends on continued clinical differentiation and the ability to fend off future generic or superior competitive therapies.
Moat Erosion Risks
- •Expiration of key patents or challenges to intellectual property rights.
- •Introduction of next-generation therapies by competitors with superior efficacy or safety profiles.
- •Failure of pipeline candidates to secure regulatory approval or demonstrate significant clinical benefit.
NUVB Competitive Moat Analysis
Sign up to see competitive advantages
NUVB Market Intelligence
Sentiment & Insider Activity
Social Sentiment
Neutral, mixed sentiment with enthusiasm for drug approval tempered by financial risks and recent share price volatility.
Institutional Sentiment
Neutral, no explicit analyst ratings provided, but ongoing positive regulatory news and clinical updates suggest potential for positive re-evaluation.
Insider Activity (Form 4)
Director Kerry Wentworth sold 200,000 shares at an average price of $4.52 (proceeds ~$904,000) on April 6, 2026, via a pre-arranged Rule 10b5-1 trading plan.
Options Flow
Normal options activity.
Earnings Intelligence
Next Earnings
Estimated early-May 2026 (for Q1 2026 results)
Surprise Probability
Medium
Historical Earnings Pattern
The stock experienced significant volatility after Q4 2025 earnings, dropping over 25% despite a revenue beat, before recovering. This indicates market sensitivity to overall financial health and future outlook beyond just top-line performance.
Key Metrics to Watch
Competitive Position
Top Competitor
N/A - specific peer data not provided in real-time intelligence
Market Share Trend
Gaining market share in the ROS1+ NSCLC segment with the recent launch of IBTROZI®.
Valuation vs Peers
Trading at a high P/S multiple for its current revenue, typical for early-stage commercial biotechs with significant growth potential, but may be at a premium compared to more established, profitable oncology companies.
Competitive Advantages
- •First-mover advantage and differentiated profile for taletrectinib in ROS1+ NSCLC post-FDA approval.
- •Experienced leadership team with a strong track record in oncology drug development (Dr. David Hung).
- •Broad and diversified precision oncology pipeline beyond taletrectinib.
Market Intelligence
Get sentiment, earnings intel, and peer analysis with Premium
What Could Drive NUVB Stock Higher?
Near-Term (0-6 months)
- •Pivotal TRUST-I/TRUST-II data presentation at AACR Annual Meeting 2026 (April 21, 2026)
- •Q1 2026 Earnings Report (Estimated early-May 2026)
- •Progress on European Marketing Authorisation Application for taletrectinib
Medium-Term (6-18 months)
- •Potential approval and launch of IBTROZI® in Europe (if EMA application is successful)
- •Clinical trial advancements for pipeline assets NUV-868 and NUV-520
- •Expansion of IBTROZI® market share and patient adoption
Long-Term (18+ months)
- •Establishment as a global precision oncology leader across multiple indications
- •Successful development and commercialization of next-generation oncology therapies
- •Strategic partnerships or M&A activities to expand pipeline or market reach
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
What's the Bull Case for NUVB?
- ✓
Acceleration in IBTROZI® revenue growth and new patient starts quarter-over-quarter.
- ✓
Positive clinical updates and progression of NUV-868 and NUV-520 through trials.
- ✓
Trends in cash burn and progress towards cash flow breakeven.
Bull Case Analysis
See what could go right with Premium
Competing with NUVB
See how Nuvation Bio Inc compares to related companies
| Company | Market Cap | DVR Score | P/E | Revenue | Profit Margin | Rev Growth | |
|---|---|---|---|---|---|---|---|
Nuvation Bio Inc NUVB | $1.6B | 8.7 | -7.7 | $62.9M | -325.3% | 0.0% | |
AbbVie Inc ABBV | $403.8B | 0.1 | 171.8 | — | — | — | Compare → |
Johnson & Johnson JNJ | — | 1.0 | — | — | — | — | Compare → |
Eli Lilly and Co LLY | $965.0B | 0.5 | 52.6 | — | — | — | Compare → |
Pfizer Inc PFE | $150.6B | 0.2 | 19.4 | $62.6B | 12.4% | -1.6% | Compare → |
UnitedHealth Group Inc UNH | $276.2B | 0.3 | 22.9 | $113.7B | 2.7% | 1181.0% | Compare → |
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
How Nuvation Bio Inc Makes Money
Nuvation Bio is a clinical-stage and newly commercial-stage biotechnology company focused on discovering, developing, and commercializing innovative precision oncology therapies for patients with difficult-to-treat cancers. The company's primary revenue source is currently through the direct sales of its FDA-approved drug, IBTROZI® (taletrectinib), used for treating ROS1-positive non-small cell lung cancer. As it expands globally and advances its pipeline, Nuvation Bio aims to generate additional revenue from new product launches and licensing agreements, targeting significant unmet medical needs in oncology.
Read Full Business Model BreakdownFAQ
What is the DVR Score for Nuvation Bio Inc (NUVB)?
As of April 12, 2026, Nuvation Bio Inc has a DVR Score of 8.7 out of 10, placing it in the "Hidden Gem" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.
What is the market capitalization of Nuvation Bio Inc?
Nuvation Bio Inc's market capitalization is approximately $1.6B. The company operates in the Healthcare sector within the Biotechnology industry.
What ticker symbol does Nuvation Bio Inc use?
NUVB is the ticker symbol for Nuvation Bio Inc. The company trades on the NYQ.
What is the risk level for NUVB stock?
Our analysis rates Nuvation Bio Inc's overall risk as Aggressive. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.
What is the P/E ratio of NUVB?
Nuvation Bio Inc currently has a price-to-earnings (P/E) ratio of -7.7. This is below the market average, which could indicate the stock is undervalued or facing headwinds.
Is Nuvation Bio Inc's revenue growing?
Nuvation Bio Inc has reported revenue growth of 0.0%. Revenue has been declining, which warrants closer examination.
Is NUVB stock profitable?
Nuvation Bio Inc has a profit margin of -325.3%. The company is currently unprofitable.
How often is the NUVB DVR analysis updated?
Our AI-powered analysis of Nuvation Bio Inc is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on April 12, 2026.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for NUVB (Nuvation Bio Inc) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.